GHRP-2
Also called Pralmorelin, KP-102
What to know about GHRP-2
GHRP-2, or pralmorelin, is a growth-hormone secretagogue that activates the ghrelin receptor. Most human literature measures short-term endocrine responses.
- How it may work
- Ghrelin-receptor activation stimulates pituitary growth-hormone release and can also influence appetite and other pituitary hormones.
- What research found
- Human studies show a rapid growth-hormone response and have explored GHRP-2 as a pituitary-function challenge. A 30-day infusion study examined repeated exposure but was not a broad outcome trial.
- What is not settled
- Short endocrine studies cannot define long-term glucose, appetite, fluid-balance, cardiac, or pituitary risks.
- Research and product status
- GHRP-2 has no licensed U.S. product. It is prohibited in sport under WADA's growth-hormone secretagogue category.
Research reference
- Research amount range
- 100–100 mcg per administration — not a starting amount
- Reference frequency
- Every day — catalogue input, not a personal schedule
- Evidence route
- Intravenous in the cited evidence; formulation matters.
- Model accumulation timescale
- ~2 hours — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
- When change was measured
- Human experiments measured growth hormone and appetite-related signals over minutes to hours. Those acute biomarkers do not establish when sleep, recovery, muscle, or body-composition outcomes appear.
- When to assess
- No robust long-duration outcome study supplies a reassessment week for commonly marketed goals. A short hormone pulse is not evidence of a durable functional change.
- Conditions and limitations
- The cited studies do not establish bedtime use, fasting, exercise timing, or pairing with a GHRH analogue as necessary for meaningful outcomes.
- When to stop
- No validated course length, maintenance phase, or quit rule exists for common research use. Lack of a felt result is not a basis for increasing frequency or extending exposure.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Key properties
- Formula
- C45H55N9O6
- Mol. weight
- 818 Da
- CAS
- 158861-67-7
- PubChem CID
- 6918245
External references
Roughly 20–30 minutes; a short-acting secretagogue.
A growth-hormone secretagogue whose human evidence is a single 100 mcg intravenous dose given as a pituitary challenge, licensed in Japan. No subcutaneous dose-ranging schedule is established, so no schedule table is shown.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 2hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Pralmorelin (GHRP-2) growth-hormone challenge program, JapanLicensed as a single 100 mcg intravenous growth-hormone secretagogue challenge; the human data is the single-dose challenge, not a subcutaneous schedule.